- Home
- CHRS
as 07-01-2025 4:00pm EST
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 84.2M | IPO Year: | 2014 |
| Target Price: | $4.68 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.66 - $2.43 | Next Earning Date: | 08-07-2025 |
| Revenue: | $272,251,000 | Revenue Growth: | 19.87% |
| Revenue Growth (this year): | -78.58% | Revenue Growth (next year): | 106.56% |
Stock Insider Trading Activity of Coherus BioSciences Inc. (CHRS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wahlstrom Mats | CHRS | Director | May 23 '25 | Sell | $0.74 | 99,988 | $73,881.13 | 0 |
Latest Coherus BioSciences Inc. News
CHRS Breaking Stock News: Dive into CHRS Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?
Insider Monkey
25 days ago
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
GlobeNewswire
a month ago
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
GlobeNewswire
a month ago
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
Simply Wall St.
2 months ago
Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations
Thomson Reuters StreetEvents
2 months ago
Q1 2025 Coherus BioSciences Inc Earnings Call
GuruFocus.com
2 months ago
Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ...
Zacks
2 months ago
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Compare CHRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CHRS Coherus BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.